Keyphrases
Diabetic Macular Edema
100%
Pharmacokinetic Evaluation
100%
Pegaptanib
100%
VEGF Blocker
57%
Patients with Diabetes
28%
Anti-VEGF Therapy
28%
Number of Patients
14%
Causes of Visual Impairment
14%
Cardiovascular Risk
14%
Clinical Efficacy
14%
Randomized Controlled Trial
14%
Visual Loss
14%
Tolerability
14%
Safety Profile
14%
Pharmacokinetics
14%
Non-responders
14%
Expert Opinion
14%
Diabetic Retinopathy
14%
Safety Self-efficacy
14%
Neovascular Age-related Macular Degeneration (nAMD)
14%
Laser Therapy
14%
Area Cover
14%
Most Common Cause
14%
Ocular Safety
14%
Blocking Agent
14%
Systemic Safety
14%
Macugen
14%
Pharmacology, Toxicology and Pharmaceutical Science
Edema
100%
Diabetes Mellitus
100%
Pharmacokinetics
100%
Vasculotropin
100%
Pegaptanib
100%
Diabetic Macular Edema
75%
Visual Impairment
25%
Cardiovascular Risk
12%
Tolerability
12%
Randomized Controlled Trial
12%
Diabetic Retinopathy
12%
Disease Predisposition
12%
Wet Macular Degeneration
12%
Blocking Agent
12%